The unique properties of IgE antibodies, including their high affinity for cognate receptors, prolonged tissue residency, engagement of tumour-resident immune effector cells and orchestration of potent effector functions, may make them well-suited for this therapeutic use. The gene discussed is IGHE; the disease is neoplasm.